Cover Image
Market Research Report
Product code 

KOL Insight: Melanoma 2020

Published: | FirstWord | Delivery time: 1-2 business days


Back to Top
KOL Insight: Melanoma 2020
Published: October 13, 2020
Delivery time: 1-2 business days
  • Description
  • Table of Contents

Must-Know Insights From The World's Foremost Thought-Leaders

Answer critical business questions with deep intelligence from those already in-the-know

Why do KOLs foresee an expansion of Merck's anti-PD-1 therapy Keytruda in the adjuvant setting? Could Eli Lilly/Innovent Biologics' sintilimab/ipilimumab biosimilar combination threaten BMS' Opdivo/Yervoy domination of advanced melanoma treatment? <>And why do KOLs believe Iovance Biotherapeutics' pipeline lifileucel has the potential to change practice for patients' refractory to multiple-lines of therapy? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.

Key questions answered:

  • Why do oncologists suggest the anti-PD1/CTLA4 blockade could be practice changing in the neoadjuvant setting?
  • Why are experts underwhelmed with Roche's triple combination of Tecentriq with Cotellic/Zelboraf?
  • Why do KOLs believe Nektar/BMS' late stage bempegaldesleukin/nivolumab combination could be a potential competitor to Opdivo/Yervoy?
  • How and where do oncologists see potential value for Idera's PIII tilsotolimod/Yervoy combination?

Examples of Therapies Covered:

  • Yervoy
  • Keytruda
  • Tafinlar/Mekinist
  • Relatlimab
  • Tilsotolimod
  • Opdivo
  • IBI310
  • Zelboraf/Cotellic
  • Spartalizumab
  • Tyvyt

Partial List of Participating KOLs:

  • Oncology Specialist, MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC.
  • Professor of Medicine (Hematology/Oncology), Roswell Park Cancer Institute, 915 CSC Building, Elm and Carlton Streets, Buffalo, NY.
  • Oncology Specialist, Professor, Moffitt Cancer Center and University of South Florida Morsani College of Medicine, Tampa, FL.
  • Professor & Chief Scientific Officer, Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands.
  • Professor of Medicine, Head of the Dermatology Unit at the Gustave Roussy Cancer Centre, Villejuif-Paris, France.
  • Professor of Medicine, University of Zurich, Vice-Chairman, Department of Dermatology, University Hospital of Zürich. Switzerland.

Table of Contents

Executive summary

Treatment algorithm

Research objectives

Marketed therapies

  • Overview
  • Immunotherapies
    • Key insights summary
    • Yervoy (ipilimumab; Bristol Myers Squibb)
    • Opdivo (nivolumab; Bristol Myers Squibb/Ono Pharmaceutical)
    • Keytruda (pembrolizumab; Merck & Co.)

BRAF/MEK inhibitors

  • Overview
    • Key insights summary
  • Marketed BRAF/MEK drugs
    • Tafinlar/Mekinist (dabrafenib/trametinib; Novartis)
    • Zelboraf/Cotellic (vemurafenib/cobimetinib; Roche)
    • Braftovi/Mektovi (encorafenib/binimetinib; Array Biopharma)

Oncolytic viruses/immunostimulants

  • Overview
    • Imlygic (talimogene laherparepvec; Amgen)

Pipeline therapies

  • Overview

CTLA4/PD-1/PDL-1/LAG-3 inhibitors

  • Overview
    • Key insights summary
    • IBI310 (ipilimumab biosimilar; Innovent Biologics)
    • Relatlimab (Bristol Myers Squibb/Ono Pharmaceuticals)
    • Spartalizumab (PDR001; Novartis)
    • Tyvyt (sintilimab; Innovent Biologics/Lilly

Toll-like receptor 9 (TLR9) agonists

  • Overview
    • Key insights summary
    • Tilsotolimod (Idera Pharmaceuticals)


  • Overview
    • Key insights summary
    • Lenvima (lenvatinib; Eisai/Merck & Co.)

Recombinant immunostimulants

  • Overview
    • Key insights summary
    • Bempegaldesleukin (Nektar/BMS)
    • Seviprotimut-L (POL 103A; Polynoma)

Early-stage pipeline drugs

  • Overview
    • Key insights summary
    • ATG-019 (KPT-9274; Karyopharm Therapeutics)
    • BI-1206 (BioInvent International)
    • BNT111 (BioNTech)
    • Ceralasertib (AstraZeneca)
    • Inlyta (axitinib; Pfizer)
    • IO102 (IO Biotech)
    • LN-144 (lifileucel; Iovance Biotherapeutics)
    • Tebentafusp (Immunocore)


  • KOL details
    • KOLs from North America
    • KOLs from Europe